New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:07 EDTSTEMStemCells closes enrollment in Phase I/II AMD trial
StemCells announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration, or AMD, in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the current AMD trial show a 70% reduction in the rate of geographic atrophy as compared to the control eye and a 65% reduction in the rate of GA as compared to the expected natural history of the disease following a single dose of the Company's proprietary HuCNS-SC human neural stem cells. In addition to these initial efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile for HuCNS-SC as a treatment for dry AMD. Final results from this landmark study are expected to be released mid-2015.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:57 EDTSTEMStemCells to host analyst day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use